A Comprehensive Molecular and Clinical Investigation of Approved Anti-HCV Drugs Repurposing against SARS-CoV-2 Infection: A Glaring Gap between Benchside and Bedside Medicine

A Comprehensive Molecular and Clinical Investigation of Approved Anti-HCV Drugs Repurposing against SARS-CoV-2 Infection: A Glaring Gap between Benchside and Bedside Medicine

The limited availability of effective treatment against SARS-CoV-2 infection is a major challenge in managing COVID-19. This scenario has augmented the need for repurposing anti-virals for COVID-19 mitigation. In this report, the anti-SARS-CoV-2 potential of anti-HCV drugs such as daclatasvir (DCV)...

Full description

Bibliographic Details
Main Authors: Sneha Bansode, Pawan Kumar Singh, Meenakshi Tellis, Anita Chugh, Narendra Deshmukh, Mahesh Gupta, Savita Verma, Ashok Giri, Mahesh Kulkarni, Rakesh Joshi, Dhruva Chaudhary
Format: Article
Language:English
Published: MDPI AG 2023-02-01
Series:Vaccines
Subjects:
antiviral
COVID-19
daclatasvir
ledipasvir
sofosbuvir
SARS-CoV-2
Online Access:https://www.mdpi.com/2076-393X/11/3/515

Internet

https://www.mdpi.com/2076-393X/11/3/515

Similar Items